Quarterly report [Sections 13 or 15(d)]

REVENUES

v3.25.1
REVENUES
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
REVENUES

NOTE 10 – REVENUES

 

Disaggregation of Net Revenues

 

The Company’s net product revenues are summarized below:

 

             
   

Three months ended
March 31,

  
    2025     2024  
Zembrace Symtouch   $ 2,026     $ 1,847  
Tosymra     403       635  
Total product revenues   $ 2,429     $ 2,482  

 

All sales are generated in the United States.

 

Gross-to-Net Sales Accruals

 

We record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary to the pharmaceutical industry.

 

Our provision for gross-to-net allowances was $5.1 million at March 31, 2025, $1.2 million of which was recorded as a reduction to accounts receivable and $3.9 million recorded as a component of accrued expenses. Our provision for gross-to-net allowances was $3.0 million at March 31, 2024, $0.6 million of which was recorded as a reduction to accounts receivable and $2.4 million recorded as a component of accrued expenses.